Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891785187> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- W2891785187 abstract "e18331 Background: Nivolumab was recently shown to improve overall survival (OS) and health-related quality of life compared to Everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with antiangiogenic therapies (CheckMate-025 trial). The aim of this study is to assess the cost-utility of Nivolumab versus Everolimus from the perspective of the Canadian publicly funded healthcare system. Methods: To evaluate the cost-utility of Nivolumab versus Everolimus, a Markov cohort model that incorporated data from the phase 3 CheckMate-025 trial and other sources was developed. The outcomes of interest were healthcare costs, life-months and quality-adjusted life-months (QALMs) gained with Nivolumab as well as the incremental cost-effectiveness ratio (ICER), and the incremental net monetary benefit. A lifetime time horizon was used in the base case with costs and outcomes discounted 5% annually. The probabilities of progression and death from cancer and utility values were captured from the CheckMate-025 trial. Expected costs were based on Ontario fees and other sources. Scenario and sensitivity analyses (SAs) were conducted to assess uncertainty. Results: Compared to Everolimus, treatment with Nivolumab provided an additional 3.9 QALMs at an incremental cost of 33,386 Canadian dollars (CAD). The resulting ICER was 8,608CAD per QALM gained. With a willingness-to-pay (WTP) of 50,000CAD per Quality-adjusted life-year (QALY) ( = 4,167CAD per QALM), Nivolumab was not cost-effective in the base case. In one-way SAs, Nivolumab cost, median OS and treatment duration on Nivolumab were sensitive to changes with plausible threshold values. Assuming a WTP of 100,000CAD per QALY ( = 8,334CAD per QALM) and a scenario of Nivolumab cost with no drug wastage, Nivolumab became a cost-effective strategy with an ICER of 7,881CAD per QALM. Conclusions: With its current price , Nivolumab is unlikely to be cost-effective compared with Everolimus for previously treated mRCC patients from a Canadian healthcare payer perspective. While mRCC patients derive a meaningful clinical benefit from Nivolumab, considerations should be given to reduce drug wastage and increase the WTP threshold to render this strategy more affordable." @default.
- W2891785187 created "2018-09-27" @default.
- W2891785187 creator A5015792267 @default.
- W2891785187 creator A5032844648 @default.
- W2891785187 creator A5033181043 @default.
- W2891785187 creator A5034319315 @default.
- W2891785187 creator A5048366969 @default.
- W2891785187 date "2017-05-20" @default.
- W2891785187 modified "2023-09-25" @default.
- W2891785187 title "Nivolumab in the treatment of metastatic renal cell carcinoma: A cost-utility analysis." @default.
- W2891785187 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18331" @default.
- W2891785187 hasPublicationYear "2017" @default.
- W2891785187 type Work @default.
- W2891785187 sameAs 2891785187 @default.
- W2891785187 citedByCount "0" @default.
- W2891785187 crossrefType "journal-article" @default.
- W2891785187 hasAuthorship W2891785187A5015792267 @default.
- W2891785187 hasAuthorship W2891785187A5032844648 @default.
- W2891785187 hasAuthorship W2891785187A5033181043 @default.
- W2891785187 hasAuthorship W2891785187A5034319315 @default.
- W2891785187 hasAuthorship W2891785187A5048366969 @default.
- W2891785187 hasConcept C121608353 @default.
- W2891785187 hasConcept C126322002 @default.
- W2891785187 hasConcept C143998085 @default.
- W2891785187 hasConcept C2777472916 @default.
- W2891785187 hasConcept C2777546739 @default.
- W2891785187 hasConcept C2777701055 @default.
- W2891785187 hasConcept C2780030458 @default.
- W2891785187 hasConcept C71924100 @default.
- W2891785187 hasConceptScore W2891785187C121608353 @default.
- W2891785187 hasConceptScore W2891785187C126322002 @default.
- W2891785187 hasConceptScore W2891785187C143998085 @default.
- W2891785187 hasConceptScore W2891785187C2777472916 @default.
- W2891785187 hasConceptScore W2891785187C2777546739 @default.
- W2891785187 hasConceptScore W2891785187C2777701055 @default.
- W2891785187 hasConceptScore W2891785187C2780030458 @default.
- W2891785187 hasConceptScore W2891785187C71924100 @default.
- W2891785187 hasLocation W28917851871 @default.
- W2891785187 hasOpenAccess W2891785187 @default.
- W2891785187 hasPrimaryLocation W28917851871 @default.
- W2891785187 isParatext "false" @default.
- W2891785187 isRetracted "false" @default.
- W2891785187 magId "2891785187" @default.
- W2891785187 workType "article" @default.